Accelerated Maturation of Human Stem Cell-Derived Pancreatic Progenitor Cells into Insulin-Secreting Cells in Immunodeficient Rats Relative to Mice

Jennifer E. Bruin,1 Ali Asadi,1 Jessica K. Fox,1 Suheda Erener,1 Alireza Rezania,2 and Timothy J. Kieffer1,3,*
1Laboratory of Molecular and Cellular Medicine, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
2BetaLogics Venture, Janssen R&D LLC, 1000 Route 202 South, Room J108A, Raritan, NJ 08869, USA
3Department of Surgery, University of British Columbia, 950 West 10th Avenue, Vancouver, BC V5Z 1M9, Canada
*Correspondence: tim.kieffer@ubc.ca http://dx.doi.org/10.1016/j.stemcr.2015.10.013
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

SUMMARY

Pluripotent human embryonic stem cells (hESCs) are a potential source of transplantable cells for treating patients with diabetes. To investigate the impact of the host recipient on hESC-derived pancreatic progenitor cell maturation, cells were transplanted into immunodeficient SCID-beige mice or nude rats. Following the transplant, basal human C-peptide levels were consistently higher in mice compared with rats, but only rats showed robust meal- and glucose-responsive human C-peptide secretion by 19–21 weeks. Grafts from rats contained a higher proportion of insulin:glucagon immunoreactivity, fewer exocrine cells, and improved expression of mature β cell markers compared with mice. Moreover, ECM-related genes were enriched, the collagen network was denser, and blood vessels were more intricately integrated into the engrafted endocrine tissue in rats relative to mice. Overall, hESC-derived pancreatic progenitor cells matured faster in nude rats compared with SCID-beige mice, indicating that the host recipient can greatly influence the fate of immature pancreatic progenitor cells post-transplantation.

INTRODUCTION

Patients with type 1 diabetes suffer from a severe deficiency in insulin production by pancreatic islets as a result of immune-mediated destruction of pancreatic β cells. Insulin independence can be achieved by transplantation of cadaveric human islets (Shapiro, 2011), but because of the scarcity of donor tissue, the field is exploring the potential use of scalable human embryonic stem cell (hESC)-derived pancreatic cells as an alternative cell source. We have demonstrated previously that hESC-derived pancreatic progenitor cells develop over several months in vivo into insulin-secreting cells capable of reversing hyperglycemia in a mouse model of type 1 diabetes (Rezania et al., 2012, 2013; Bruin et al., 2013). Interestingly, the maturation process was accelerated when mice were exposed to chronic hyperglycemia but unaffected by exposure to long-term insulin therapy, short-term exendin-4 treatment, oral anti-diabetic medications, or high-fat diets (Bruin et al., 2013, 2015). In addition, we recently reported a revised differentiation protocol that generated glucose-responsive insulin-secreting cells in vitro and required a much shorter maturation period (~6 weeks) following transplantation to reverse hyperglycemia in mice (Rezania et al., 2014). Given the uncertainty surrounding the complex host environment and variables that may affect the maturation process in vivo, advancing the differentiation protocols in vitro prior to transplantation may be advantageous. Nevertheless, hESC-derived pancreatic progenitor cells are currently being tested for safety, tolerability, and efficacy in a phase 1/2 clinical trial by Viacyte (ClinicalTrials.gov identifier NCT02239354). Therefore, although newer differentiation protocols have been reported (Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015), it remains important to understand the development of pancreatic progenitor cells in vivo because clinical trials are underway in patients with diabetes.

There are several obvious differences between the preclinical transplant recipients tested to date (immunodeficient mice) and the target patient population, including the species, distinct metabolic profiles, and large size difference. Although rats are not directly comparable with humans, their physiology is reportedly more similar to humans than mice, particularly in terms of cardiovascular parameters (Davies and Morris, 1993). We have demonstrated previously that hESC-derived grafts were capable of robust glucose-stimulated insulin secretion (GSIS) after just 14 weeks in nude rats, whereas GSIS was not observed until after 30 weeks in similar studies with severe combined immunodeficiency (SCID)-beige mice (Rezania et al., 2012). However, these studies were performed at different facilities and with different batches of cells, so we could not make direct comparisons between species. Interestingly, others have reported that hESC-derived pancreatic progenitor cells did not efficiently differentiate into pancreatic endocrine tissue following transplantation in nude rats (Matveyenko et al., 2010). The authors speculated that the nude rat may be a less accommodating host environment compared with immunodeficient mice (Matveyenko et al., 2010). To address these conflicting observations, we...
performed a carefully controlled study within a single research facility to directly compare the in vivo development of hESC-derived pancreatic progenitor cells from the same preparation and transplanted in parallel into either immunodeficient nude rats or SCID-beige mice.

RESULTS

hESC-Derived Insulin-Producing Cells Develop Faster and Function Better in Rats Than in Mice

Pluripotent H1 cells were differentiated into pancreatic progenitor cells over 14 days, resulting in a population containing 17% endocrine cells (synaptophysin+). Chromogranin+ endocrine cells, coexpressed NKX2.2 but were largely negative for NKX6.1, a sign of immaturity (Figure S1). The differentiated cells were ~80% PDX1+, ~50% NKX6.1+, ~18% PAX6+, and ~15% Ki67+ (Figure S1). Pluripotent cells (OCT3/4+) were not detected in the differentiated population at the time of transplantation (Figure S1). This preparation of pancreatic progenitor cells was then transplanted under the kidney capsule of either SCID-beige mice (~5 million cells) or nude rats (~7 million cells). To determine whether increasing the number of transplanted cells would affect maturation in vivo, we also compared glucose-stimulated human C-peptide secretion at 28 weeks following transplantation of either 5, 10, or 20 million hESC-derived progenitor cells in a separate study (Figure S2). Although the amount of human C-peptide tended to increase with the higher doses of cells, the degree of glucose-responsiveness (indicated by the C-peptide stimulation index) of hESC-derived cells did not differ between doses (Figure S2).

At the time of transplantation, nude rats weighed ~ ten times more than SCID-beige mice on average (Figure S3A), but rats were transplanted with less than two times the amount of cells (Figure S3B). Therefore, although the kidney grafts in rats were slightly larger than in mice (Figures S3C and S3E), they were not scaled proportionately relative to the profound difference in body weight and, consequently, blood volume of the host (Figure S3D). Interestingly, despite this discrepancy in dosing, plasma human C-peptide concentrations were indistinguishable between species after a meal challenge (Figure 1A). However, rats had significantly lower basal human C-peptide levels compared with mice between 19 and 32 weeks post-transplantation (Figure 1A), which translated into an improved stimulation index for meal-induced human C-peptide secretion (Figure S4). At just 19 weeks, hESC-derived cells from rats secreted significantly more human C-peptide under fed versus fasted conditions, whereas there was no meal response by engrafted cells in mice at any stage (Figure 1A; Figure S4). Blood glucose levels were similar between species after an overnight fast, but mice had consistently higher glucose excursions following a meal compared with rats at all ages examined, regardless of graft maturity (Figure 1B). Mice also experienced significantly higher glucose excursions during an oral glucose challenge relative to rats (Figure 1C). Glucose-stimulated human C-peptide secretion was observed in rats at 21 weeks post-transplantation, whereas human C-peptide levels dropped below baseline levels following the glucose challenge in mice (Figure 1D). There was a trend toward lower basal human C-peptide levels after a 6-hr fast in rats compared with mice, although this did not reach statistical significance (p = 0.06; Figure 1E). Under random-fed conditions, human insulin, glucagon, and GLP-1 levels were all significantly lower in rats relative to mice at 22 or 33 weeks post-transplantation (Figure 1F).

Kidney Capsule Grafts from Rats Contain More Mature β Cells Than Those Harvested from Mice

At 22/33 weeks post-transplantation, grafts from rats expressed significantly higher levels of mature β cell genes, including INS, NKX6.1, MAFA, PAX6, ABCC8, PCSK1, and IAPP, as well as significantly lower levels of the immature pancreatic endocrine marker NEUROG3 and mature α cell genes, GCG and ARX, relative to grafts from mice (Figure 2). Furthermore, grafts from rats contained approximately three times more insulin relative to glucagon immunoreactivity, whereas glucagon immunoreactivity was almost twice as prevalent as insulin in grafts from mice (Figures 3A and 3C). Glucagon-positive cells in both species uniformly co-expressed the α cell transcription factor ARX (Figure S5A). Relative to the total endocrine area, grafts from rats were ~40%–50% insulin-positive, whereas grafts from mice were ~10%–25% insulin-positive (Figures 3A and 3C). There also appeared to be more pancreatic polypeptide (PP)-positive cells in grafts from rats, although cells expressing PP, somatostatin, or ghrelin were much less prominent and, therefore, not quantified (Figure S5B). At the gene level, there were no differences in SST or PPY expression between species, but grafts from mice had approximately two times more GHRL transcript compared with grafts from rats (Figure 2). Overall, hESC-derived progenitor cells developed more efficiently into the endocrine lineage in rats compared with mice, as indicated by the significantly reduced trypsin-positive area (Figures 3B and 3D), higher proportion of synaptophysin:trypsin immunoreactivity (Figures 3B and 3D), and decreased gene expression of the exocrine marker PTF1A in grafts from rats versus mice (Figure 2). The presence of non-endodermal germ layers was not detected in kidney capsule grafts from either species (Table S1), unlike grafts generated with our earlier differentiation protocol that, on occasion, contained regions of bone and cartilage tissues (Rezania et al., 2012).
Figure 1. Improved Glycemic Control and Better Graft Function in Rats Compared with Mice

(A and B) Human C-peptide (A) and blood glucose levels (B) after an overnight fast and 45 min following an oral mixed meal between 9–32 weeks post-transplantation (n = 4–11 animals/group). *p < 0.05, paired t test (fast versus fed); #p < 0.05, one-way ANOVA with Student-Neuman-Keuls (SNK) test.

(C–E) Blood glucose (C) and human C-peptide levels (D and E) following a 6-hr morning fast and subsequent oral glucose challenge at 21 weeks post-transplantation (n = 10–11 animals/group). Human C-peptide levels are presented as (D) fold change relative to basal (red dashed line) or (E) raw values at time 0. For line graphs, *p < 0.05, two-way repeated-measures ANOVA with Sidak post hoc test (mouse versus rat). For area under the curve, *p < 0.05, ***p < 0.001; two-tailed t test.

(F) Plasma human insulin, glucagon, and GLP-1 levels at 22 or 33 weeks post-transplantation (n = 10 animals/group). The black dashed line indicates the lower limit of detection for each analyte. **p < 0.01, two-tailed t test.

Data are presented as mean ± SEM plus individual biological replicates in bar graphs. See Figure S4 for the human C-peptide stimulation index following meal challenges.
However, ducts associated with mucin and goblet cells, which are atypical of pancreatic duct morphology, were detected in several grafts from both species (Table S1). The independent pathology analysis is provided in Table S1.

Because the higher levels of mature β cell genes in grafts from rats may simply reflect the higher proportion of β cells, we next examined protein expression for a range of mature β cell markers to assess the maturation status of individual hESC-derived insulin-positive cells. Expression of the β cell transcription factors PDX1, NKX6.1, and NKX2.2 was similar between species (Figure 4A). However, MAFA expression was highly heterogeneous in grafts from mice, ranging from weak or absent to strong nuclear immunoreactivity within the insulin-positive cell population (Figure 4B, white arrows). In contrast, MAFA immunoreactivity was consistently robust and nuclear within insulin-positive cells in grafts from rats, which supports the observed ~8-fold increase in MAFA gene levels in grafts from rats compared with mice (Figure 2). Thyroid hormone was recently reported to be a physiological stimulus for β cell maturation in neonatal rats and to regulate Mafa expression (Aguayo-Mazzucato et al., 2013). Interestingly, we found that endogenous total triiodothyronine (T3, active thyroid hormone) levels were more than twice as high in rats than in mice at 22 weeks post-transplantation (mice, 0.761 ± 0.11 ng/ml; rats, 1.84 ± 0.15 ng/ml; n = 6/species).

SERPINB2 (serpin peptidase inhibitor, clade B [ovalbumin], member 2) and DGCR2 (DiGeorge syndrome critical region gene 2) were recently reported to be unique markers of mature β cells (Lindskog et al., 2012). We observed robust SERPINB2 and DGCR2 immunoreactivity in adult human β cells and grafts from rats compared with heterogenous expression in both immature human fetal β cells and grafts from mice (Figure S6). Another
Figure 3. Grafts from Rats Contained a Higher Proportion of Insulin:Glucagon and Synaptophysin:Trypsin Immunoreactivity Compared with Grafts from Mice
(A and B) Representative immunofluorescence images of whole hESC-derived grafts (graft and kidney tissue is delineated by a dashed white line; scale bars, 500 μm) and higher-magnification insets (scale bars, 100 μm) at 22 weeks post-transplantation. Shown are (A) insulin (red) and glucagon (green) and (B) synaptophysin (red, endocrine marker) and trypsin (green, exocrine marker). DAPI nuclear staining is shown in gray in all images.
(C) Area of insulin (ins) or glucagon (gcg) immunoreactivity relative to total synaptophysin immunoreactivity and insulin+ area relative to glucagon+ area for each graft.
(D) Area of synaptophysin or trypsin immunoreactivity relative to the total graft area and synaptophysin+ area relative to trypsin+ area for each graft.
*p < 0.05, **p < 0.01; two-tailed t test. All data are presented as mean ± SEM plus individual biological replicates (n = 3 animals/group). See Figure S5 for additional immunofluorescent staining of hESC-derived grafts.
Figure 4. hESC-Derived Insulin-Positive Cells from Both Species Expressed Similar β Cell Transcription Factors Except MAFA Expression Was More Heterogenous in Mice.
(A) Representative immunofluorescent staining of engrafted cells for insulin (red), glucagon (blue), and various transcription factors (green): PDX1, NKX6.1, and NKX2.2 (scale bars, 100 μm).
(B) Three different regions of insulin-positive cells (red) from each graft illustrate the heterogeneity in nuclear MAFA expression (green; white arrows show examples of insulin-positive cells without nuclear MAFA immunoreactivity). Scale bars, 50 μm. DAPI nuclear staining is shown in gray.
See Figure S6 for additional immunofluorescent staining of mature β cell markers in hESC-derived grafts.
A feature of mature β cells is the presence of prohormone convertase enzymes, which convert proinsulin into mature insulin and C-peptide (Asadi et al., 2015). PCSK1 gene expression was significantly higher in grafts from rats compared with mice (Figure 2), and almost all engrafted insulin-positive cells coexpressed PC1/3 in rats (Figure 5). Proinsulin immunoreactivity in grafts from rats was also uniformly punctate and perinuclear (Figure 5), suggesting that non-processed proinsulin is localized within the trans-Golgi network, as expected in human β cells (Asadi et al., 2015). In contrast, engrafted insulin-positive cells in mice contained highly heterogenous and generally weaker coexpression of PC1/3, which resulted in diverse patterns of proinsulin immunoreactivity, including cells with intense perinuclear and/or cytoplasmic immunoreactivity (Figure 5). Collectively, graft analysis indicates that hESC-derived progenitor cells developed into a more mature pancreatic endocrine phenotype in rats compared with mice, with a bias toward the development of β cells instead of α cells.

Grafts from Rats Are Better Vascularized and Express Higher Levels of Genes Involved in Extracellular Matrix Organization Than Grafts from Mice

Since vascularization is a critical factor for islet graft survival and function post-transplantation (Pepper et al., 2013), we measured a panel of secreted human proteins related to angiogenesis. Mice had significantly higher circulating levels of human vascular endothelial growth factor C (VEGF-C) and basic fibroblast growth factor (bFGF) than rats, but all other angiogenic proteins were similar between species (Figure 6A). Interestingly, we also observed a clear increase in the density and distribution of red blood cells in grafts from rats compared with mice (Figure 6B; red blood cell area as percent of total graft area; mice, 0.95% ± 0.33%; rats, 4.44% ± 1.40%), suggesting that hESC-derived grafts were better vascularized in rats. Lectins (e.g., wheat germ agglutinin [WGA]) are carbohydrate-binding proteins commonly used for marking vasculature (Jilani et al., 2003; Robertson et al., 2015). Substantial lectin staining was observed in grafts from mice and rats, indicating that both were highly vascularized, but lectin...
Figure 6. Engrafted hESC-Derived Cells Were More Highly Vascularized in Rats than in Mice

(A) Plasma levels of angiogenesis-related secreted proteins at 22 or 33 weeks post-transplantation (n = 9–11 animals/group). The dashed black line indicates the lower limit of detection on each assay. **p < 0.01, two-tailed t test. Data are presented as mean ± SEM plus individual biological replicates.

(B) Examples of autofluorescent red blood cells (green) among hESC-derived, insulin-positive endocrine tissue (red) in grafts from mice and rats at 22 weeks post-transplantation. Scale bars, 100 μm.

(C) Representative immunofluorescent staining of hESC-derived cells at 22 weeks post-transplantation for insulin (red) and lectin (wheat germ agglutinin, green). DAPI nuclear staining is shown in gray for all images. Kidney and graft tissues are delineated by dashed white lines, and white boxes indicate regions shown at higher magnification below. Scale bars, 200 μm (low-magnification images) and 20 μm (high-magnification insets).
staining was noticeably increased within insulin-positive, islet-like structures in grafts from rats (Figure 6C).

To investigate other pathways that may be involved in promoting β cell maturation in rats, we performed an unbiased gene chip analysis of hESC-derived graft tissue from both species at 22 weeks post-transplantation. Notably, these data revealed robust upregulation of genes related to extracellular matrix (ECM) structure and organization in grafts from rats compared with mice (Figure 7A). For example, five genes from the collagen family (COL3A1, COL1A1, COL1A2, COL6A3, and COL1A2) were all upregulated more than 13-fold in grafts from rats compared with mice, along with genes such as LUM (lumican), VCAN (versican), FBN1 (fibrillin 1), and DCN (decorin), which all encode for important structural components of the ECM (Figure 7A). A list of genes that were significantly enriched >5-fold in mouse grafts relative to rat grafts is provided in Table S2. To further investigate the observed changes in ECM-related genes, we next examined circulating levels of human matrix metalloproteinases (MMPs), which are involved in matrix remodeling. Interestingly, at both 22 and 33 weeks post-transplantation, rats had significantly higher plasma levels of human MMP1 and reduced MMP3 levels compared with mice (Figure 7B). MMP9 levels were not different between species (data not shown). Masson’s trichrome staining of engrafted cells confirmed that there were clear differences in the ECM between species (Figure 7D). Grafts in rats were supported by a highly dense collagen layer on the outer surface of the kidney capsule as well as a compact collagen network intricately embedded throughout the hESC-derived cells, whereas grafts in mice contained less collagen overall, and the collagen network was much looser and stained lighter (Figure 7D). Masson’s trichrome staining of adult human pancreas tissue demonstrated that human islets are normally supported by a complex collagen matrix both on the periphery and also embedded throughout the islet core (Figure 7C).

Metal-binding metallothioneins (MT1G, MT1X, and MT2A) were also robustly upregulated in grafts from rats compared with mice (Figure 7A). In rodent and human β cell lines (INS1 and EndoC-βH1, respectively), we found that MT1 expression was profoundly upregulated in response to cellular stress, including exposure to interleukin 1β (IL-1β) alone, a cytokine cocktail (tumor necrosis factor α [TNFα], IL-1β, and interferon γ [IFNγ]), or H2O2 (Figure 7A). To determine whether engrafted cells from mice and rats produced different cytokine profiles, we measured a panel of human cytokines in the circulation at 22 and 33 weeks post-transplantation. Interestingly, most of the cytokines measured were near or below the limit of detection, including MIP1β, MCP-1, MCP-4, IP-10, thymus- and activation-regulated chemokine (TARC), Eotaxin, Eotaxin-3, and macrophage-derived chemokine (MDC) (Figure S7B). In contrast, human IL-8 levels were well into the linear detection range of the assay for the majority of samples and were significantly higher in mice compared with rats (Figure S7B).

**DISCUSSION**

Following transplantation into immunodeficient mice, immature hESC-derived pancreatic progenitor cells develop over a lengthy maturation period into glucose-responsive, insulin secreting cells (Rezania et al., 2012; Bruin et al., 2013), although this process remains poorly understood. The aim of this study was to determine whether the host species affects the development of hESC-derived progenitor cells in vivo. Interestingly, cells engrafted into nude rats secreted human C-peptide in response to both meal and glucose challenges at a much earlier time compared with cells transplanted into SCID-beige mice. Furthermore, grafts from rats contained a significantly higher proportion of mature β cells, increased expression of ECM-related genes, a more complex collagen matrix, and improved vascularization compared with grafts from mice. These data confirm our previous observation that hESC-derived, insulin-secreting cells were glucose-responsive after a relatively short (14-week) maturation period in nude rats (Rezania et al., 2012), and our head-to-head comparison of mice versus rats indicates that this accelerated maturation can likely be attributed to environmental factors within the host milieu.

Based largely on evidence from preclinical studies in immunodeficient mice (Kroon et al., 2008; Kelly et al., 2011; Rezania et al., 2012, 2013; Bruin et al., 2013; Motté et al., 2014), the safety of hESC-derived pancreatic progenitor cells is now being evaluated clinically in a small cohort of patients with type 1 diabetes. However, ongoing preclinical studies in rodent models are still necessary to predict how progenitor cells may behave in a widely variable patient population. Although rats are not an ideal model for humans, their physiology is reportedly more similar to humans than mice (Davies and Morris, 1993). Blood glucose levels in healthy humans typically range from 4.4–6.1 mM and can rise to nearly 7.8 mM after a full meal (International Diabetes Federation, 2011). Similarly, nude rats in our study had fasting blood glucose levels of between ~3–5 mM and an average peak of 5.5 or 6.7 mM following a meal or glucose challenge, respectively. Unlike humans and rats, SCID-beige mice had relatively high fasting glucose levels (average of 7.2 mM) and dramatic glucose fluctuations peaking at 10 or 18 mM, on average, following a meal or glucose challenge, respectively.

Stem Cell Reports | Vol. 5 | 1081–1096 | December 8, 2015 | ©2015 The Authors
Figure 7. Grafts from Rats Were Enriched for Genes Related to Extracellular Matrix Composition and Remodeling and Were Densely Integrated with Collagen Fibers

(A) List of all genes significantly enriched >5-fold in grafts from rats relative to mice at 22 weeks post-transplantation based on microarray analysis (n = 3 animals/group).

(legend continued on next page)
Another advantage of moving to a larger model is the insight gained into scaling up cell dosing to accommodate a larger transplant recipient. Our studies revealed that the dose of pancreatic progenitor cells does not need to be scaled proportionately with body size to produce therapeutic levels of human insulin. Rats received less than two times the amount of cells despite having approximately ten times the blood volume of mice, and, yet, circulating human C-peptide levels were similar between species. Importantly, the grafts did not simply expand to accommodate the larger host but, rather, matured into better functioning \( \beta \) cells compared with the smaller host. We also confirmed in a separate study, that implanting higher numbers of progenitor cells itself does not affect the glucose responsiveness of hESC-derived insulin-secreting cells post-transplantation. Another consideration for predicting cell dosages in humans is that rodents are relatively insensitive to human insulin (Pepper et al., 2009), meaning that fewer human progenitor cells may be required per unit of body weight to reverse diabetes in patients compared with rodent models. For instance, although diabetic mice typically require 2,000–4,000 human islet equivalents (IEQs) to achieve normoglycemia (80,000–160,000 IEQs/kg), human patients typically require only \( \sim 5,000–10,000 \) IEQs/kg (Graham et al., 2011). Taken together, these data suggest that the dose of hESC-derived progenitor cells required for humans might be lower than previously predicted based on mouse models.

The fate of hESC-derived pancreatic progenitor cells differed substantially following transplantation in SCID-beige mice versus nude rats. As early as 19 weeks post-transplantation, rats had significantly lower fasting human C-peptide levels and enhanced meal- and glucose-responsive C-peptide secretion compared with mice. One possibility is that the accelerated maturation was driven by differences in immune competence between the two rodent strains. SCID-beige mice possess two autosomal recessive mutations (SCID [\( \text{Prkdc}^{scid} \) and beige [\( \text{Lyst}^{bg} \)]) that result in lack of B and T lymphocytes as well as defective natural killer (NK) cells (MacDougall et al., 1990), whereas the athymic Rowett nude (RNU) rat is deficient only in T lymphocytes (Cash et al., 1993). Interestingly, when fetal lung xenografts were implanted under the kidney capsule of SCID-beige mice versus nude rats, there were increased inflammation and signs of graft rejection by 4 weeks post-transplantation in nude rats, and the authors speculated that this was likely because of the presence of NK cells in nude rats (De Paepe et al., 2012). In contrast, pancreatic progenitor cells thrived in nude rats for up to 33 weeks in our study despite the presence of NK cells. Others have also shown that hESC-derived progenitor cells matured similarly in different strains of immunodeficient mice, including B6-TCR\( \alpha^{-/-} \) (nonfunctional T cells), B6-RAG\( ^{-/-} \) (nonfunctional T/B cells), non-obese diabetic (NOD)-SCID (nonfunctional T/B cells and impaired NK cells), and NOD-SCID \( \gamma \) (NSG) mice (nonfunctional T/B cells and nonfunctional NK cells) (Szot et al., 2015), suggesting that the immune competency of the different strains may not have been a critical factor in our study. Another possibility is that exposure to high glucose concentrations may have contributed to high basal insulin production by grafts from mice. Human \( \beta \) cells exposed to high glucose become more active under low-glucose conditions (elevated basal biosynthesis and secretion of insulin) and lose the ability to respond to acute variations in glucose concentrations (Ling and Pipeleers, 1996). These data are also supported by our previous observations that mice with chronic hyperglycemia had higher basal human C-peptide production by hESC-derived cells compared with normoglycemic mice (Bruin et al., 2013).

Rat grafts not only contained a higher proportion of insulin-secreting cells but also a more consistently mature \( \beta \) cell phenotype compared with mice, particularly for immunoreactivity of MAFA, a key transcription factor that regulates glucose-stimulated insulin secretion (Mat-suoka et al., 2004; Zhang et al., 2005; Wang et al., 2007), and PC1/3, the dominant prohormone convertase responsible for proinsulin processing (Zhu et al., 2002). Indeed, proinsulin immunoreactivity was uniformly distributed in grafts from rats as well as human pancreas (Asadi et al., 2015), indicating efficient human proinsulin processing, whereas grafts from mice contained irregular patterns of proinsulin immunoreactivity. Because \( \text{Mafa} \) is involved in regulating \( \text{Pks}^{\text{I}} \) expression (Wang et al., 2007), these differences...
may be a reflection of the improved MAFA gene expression and nuclear MAFA immunoreactivity in β cells from grafts in rats compared with mice. Thyroid hormone has been recently proposed as a physiological regulator of β cell maturation in neonatal rats via Mafa activation (Aguayo-Mazzucato et al., 2013), and addition of T3 during late stages of hESC differentiation induces MAFA expression in vitro (Rezania et al., 2014). Interestingly, the improved graft function and MAFA levels in nude rats were associated with significantly higher circulating thyroid hormone levels. Therefore, future studies should investigate how modulating thyroid hormone levels in vivo may affect the maturation of hESC-derived β cells.

We performed an unbiased gene profile of immature grafts from mice versus mature grafts from rats at 22 weeks post-transplantation to uncover other pathways associated with improved human β cell maturation in vivo. The most striking finding was that grafts from rats were dramatically enriched for genes related to the structural stability of the ECM, including numerous collagens (COL3A1, COL1A1, COL1A2, COL6A3, and COL1A2), lumican, versican, and others. We also noted a dramatic, ~25-fold increase in SPARC, a gene that encodes a matricellular protein involved in mediating the interaction between cells and the ECM via regulation of collagen (Breken and Sage, 2001), in grafts from rats compared with mice. Interestingly, SPARC gene expression has been strongly associated with the degree of glucose-stimulated insulin secretion in isolated human islets, and overexpression of SPARC in cultured rat β cells enhanced glucose-stimulated insulin secretion (Harries et al., 2013). There is also substantial evidence that reconstructing the islet cell-ECM relationship following islet isolation improves cell survival and function both in vitro and following islet transplantation in vivo (Nagata et al., 2001; Hammar et al., 2004; Kaido et al., 2004; Navarro-Alvarez et al., 2008; Salvay et al., 2008; Jalili et al., 2011; Yap et al., 2013). For example, islets embedded within a collagen matrix displayed enhanced glucose-stimulated insulin secretion (Nagata et al., 2001; Jalili et al., 2011; Yap et al., 2013). Similarly, hESC-derived cells with glucose-responsive insulin secretion in rats were embedded in a far more dense and elaborate collagen network compared with the non-responsive insulin-secreting cells in mice. Although these data suggest an association between improved human β cell maturation and the composition of the ECM in the host, it still remains to be determined whether the increased ECM network within rats was a causal factor driving the maturation of hESC-derived β cells.

Our gene chip analysis also revealed a robust upregulation of metallothionein (MT) family members that are involved in metal metabolism and detoxification, as well as reactive oxygen species (ROS) scavenging. Overexpression of MT has been shown to protect mice from streptozotocin (STZ)-induced β cell damage and diabetes (Chen et al., 2001) and to improve islet graft survival following transplantation by protecting islets from hypoxia (Li et al., 2004). Therefore, the robust induction of MT1/2 in grafts from rats may have contributed to the improved function of hESC-derived β cells by providing protection from the generally hypoxic transplant environment. Engrafted endocrine cells were more highly vascularized in rats than in mice, which may also contribute to protecting the developing β cells from hypoxia and providing more rapid delivery of nutrients for promoting secretagogue-induced secretory responses. We also demonstrated that MT1 expression is highly inducible in rodent and human β cell lines by various cell stress pathways, including exposure to ROS or cytokines. Interestingly, ROS stimulation has been shown recently to enhance β cell differentiation in pancreatic explants ex vivo, and reducing ROS production in vivo resulted in decreased β cell differentiation (Hoarau et al., 2014). Grafts from mice produced ~6-fold more IL-8 than rats, a proinflammatory cytokine that is highly secreted from human islets after culture and into the serum of human islet transplant recipients (Citro et al., 2012). Notably, peri-transplantation administration of reparixin (an IL-8 receptor inhibitor) improved islet graft function and survival in both mice and humans (Citro et al., 2012). Therefore, reducing IL-8 secretion by hESC-derived grafts or preventing IL-8 action post-transplantation may be beneficial to progenitor cell development.

Taken together, these studies provide several clues for understanding the accelerated development of hESC-derived, glucose-responsive β cells within rats, including improved integration of the ECM and vasculature with engrafted cells; induction of metallothionein proteins as a protective response to cellular stress; exposure to lower circulating glucose levels in vivo; higher endogenous thyroid hormone levels, which may contribute to induction of MAFA; and reduced IL-8 secretion by grafts. Clearly further work is required to elucidate the exact mechanism(s) underlying the in vivo development of hESC-derived β cells. These studies also highlight the susceptibility of pancreatic progenitor cells to variation within the host environment. Implantation of progenitor cells into closely related but different species revealed substantial differences in the fate choice between pancreatic endocrine versus exocrine lineages as well as z versus β cell lineages. Because the maturation environment may differ amongst human recipients, future studies should continue to investigate the role of host physiology on progenitor cell differentiation and function following transplantation. Efforts to generate bona fide mature human β cells in vitro (Pagliuca et al.,...
should also be pursued to minimize the maturation window required in vivo.

**EXPERIMENTAL PROCEDURES**

**In Vitro Differentiation of hESCs**
The H1 hESC line was obtained from the WiCell Research Institute. All experiments at the University of British Columbia (UBC) with H1 cells were approved by the Canadian Stem Cell Oversight Committee and UBC Clinical Research Ethics Board. H1 cells were cultured and differentiated according to our previously published 14-day, four-stage protocol (Bruin et al., 2013). Pancreatic progenitor cell quality was assessed by fluorescence-activated cell sorting (FACS) prior to transplantation, as described previously (Rezania et al., 2012). Details about FACS antibodies are provided in Table S3.

**Animal Studies**
All experiments were approved by the UBC Animal Care Committee. Male 8- to 10-week-old SCID-beige mice (C.B-10/H-1b/GhmsTac-PrrkΔ14-LysP80N7, Taconic) and male 8- to 10-week-old nude rats (Crl:NH-Fao1nu, Charles River Laboratories) were maintained on a 12-h light/dark cycle with ad libitum access to a standard irradiated diet (Teklad diet no.2918, Harlan Laboratories).

**Transplantation of HESC-Derived Pancreatic Progenitor Cells**
Animals were anesthetized with inhalable isoflurane and received transplants of HESC-derived pancreatic progenitor cells under the left kidney capsule. For the dose-response study (Figure S2), mice received either 5, 10, or 20 million cells (n = 5–6/group). For the mouse versus rat study, 5 million cells were transplanted into SCID-beige mice (n = 12) and 7 million cells into rats (n = 12) on the same day. Pancreatic progenitor cells were generated from the same differentiation experiment (Figure S1) and divided between the transplant recipients. Progenitor cell clusters were drawn up into PE50 tubing (Intramedic polyethylene tubing, BD Biosciences, catalog no. 427411) using a mechanical micro-manipulator. The tubing was sealed with Ligaclips (Ethicon BD Biosciences, catalog no. 427411) using a mechanical micro-manipulator. The tubing was sealed with Ligaclips (Ethicon BD Biosciences, catalog no. 427411) using a mechanical micro-manipulator.

**Histology and Immunofluorescent Staining**
Engrafted kidneys were harvested at 22 weeks post-transplantation (n = 3/species) and processed for paraffin sectioning as described previously (Asadi et al., 2015). H&E and Masson's trichrome staining were performed using standard protocols and scanned using a ScanScope CS system (Aperio). H&E-stained kidney grafts were analyzed by an independent pathologist for the presence of non-pancreatic tissue and teratoma formation (Wax-it Histology Services; Table S1). Immunofluorescent staining and imaging were performed as described previously (Asadi et al., 2015). Antibody information is provided in Table S4. Vasculature was visualized by staining with lectin (WGA, catalog no. W11261, Life Technologies), which binds to sialic acid and N-acetylgalactosaminyl residues. Quantification of graft immunoreactivity is described in the Supplemental Experimental Procedures. Human fetal pancreas (gestational week 13) was collected according to protocols approved by the Health Sciences Research Ethics Board at the University of Western Ontario. Adult human pancreas tissue was provided by the Irving K. Barber Human Islet Isolation Laboratory with consent to use it for research purposes.

**RNA Analysis**
At 22 weeks (n = 3/species) or 33 weeks (n = 4–5/species) post-transplantation, graft tissue was trimmed from the kidney of a subset of animals and stored in RNAlater (Life Technologies) at −80°C. RNA
was isolated, and gene expression was assessed by real-time PCR with custom Taqman arrays (Applied Biosystems) as described previously (Rezania et al., 2012). Details about RNA isolation from INS1 and EndoC-bH1 cells and subsequent qPCR analysis are described in the Supplementary Experimental Procedures. Human islets from a 58-year-old, non-diabetic female were used as a positive control. Data were normalized to an internal housekeeping gene (GAPDH) using the ΔΔCt method. Information regarding primers is provided in Table S5.

Genome-wide analysis was performed on grafts at 22 weeks post-transplantation using the Affymetrix HG U133+ PM array strip (Affymetrix, catalog no. PN 901569). Details about gene chip analysis are provided in the Supplementary Experimental Procedures.

Statistical Analysis
All statistics were performed using GraphPad Prism software. Specific statistical tests for each experiment are described in the figure legends. For all analyses, p < 0.05 was considered statistically significant. For area under curve analysis, y = 0 was considered the baseline. All data are presented as mean ± SEM with individual biological replicates shown as separate data points.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and five tables and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2015.10.013.

AUTHOR CONTRIBUTIONS
J.E.B. wrote the manuscript. J.E.B., A.R., and T.J.K. contributed to the conception and design of the experiments. J.E.B., A.A., J.K.F., and A.R. were responsible for the acquisition, analysis, and interpretation of data. All authors contributed to manuscript revisions and approved the final version of the manuscript.

ACKNOWLEDGMENTS
This work was funded by the Canadian Institutes of Health Research (CIHR) Regenerative Medicine and Nanomedicine Initiative, Stem Cell Network (SCN), JDRF, and Stem Cell Technologies. J.E.B. and S.E. were both funded by JDFR postdoctoral fellowships. J.E.B. was also generously funded by a CDA postdoctoral fellowship, the CIHR Transplantation Training Program, and a L’Oreal Canada for Women in Science Research Excellence Fellowship. We thank Dr. Rennian Wang for generously providing the human fetal pancreas tissue and Drs. Garth Warnock and Ziliang Ao for the adult human pancreas tissue. We also thank Ms. Diana S. Rosman-Balzer for assistance with gene chip analysis. A.R. is an employee and shareholder of Janssen R&D, LLC. T.J.K. received financial support from Janssen R&D, LLC for the research described in this article.

Received: June 9, 2015
Revised: October 22, 2015
Accepted: October 23, 2015
Published: November 19, 2015

REFERENCES
Aguayo-Mazzucato, C., Zavacki, A.M., Marinelarena, A., Hollister-Lock, J., El Khattabi, I., Marsili, A., Weir, G.C., Sharma, A., Larsen, P.R., and Bonner-Weir, S. (2013). Thyroid hormone promotes post-natal rat pancreatic β-cell development and glucose-responsive insulin secretion through MAFA. Diabetes 62, 1569–1580.
Asadi, A., Bruin, J.E., and Kieffer, T.J. (2015). Characterization of antibodies to products of proinsulin processing using immunofluorescence staining of pancreas in multiple species. J. Histochem. Cytochem. 63, 646–662.
Breken, R.A., and Sage, E.H. (2001). SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19, 816–827.
Bruin, J.E., Rezania, A., Xu, J., Narayan, K., Fox, J.K., O’Neil, J.J., and Kieffer, T.J. (2013). Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia 56, 1987–1998.
Bruin, J.E., Saber, N., Braun, N., Fox, J.K., Moijibian, M., Asadi, A., Drohan, C., O’Dwyer, S., Rosman-Balzer, D.S., Swiss, V.A., et al. (2015). Treating diet-induced diabetes and obesity with human embryonic stem cell-derived pancreatic progenitor cells and anti-diabetic drugs. Stem Cell Reports 4, 605–620.
Cash, J.M., Remmers, E.F., Goldmuntz, E.A., Crofford, L.J., Zha, H., Hansen, C.T., and Wilder, R.L. (1993). Genetic mapping of the athymic nude (RNU) locus in the rat to a region on chromosome 10. Mamm. Genome 4, 37–42.
Chen, H., Carlson, E.C., Pellet, L., Moritz, J.T., and Epstein, P.N. (2001). Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 50, 2040–2046.
Citro, A., Cantarelli, E., Maffi, P., Nano, R., Melzi, R., Mercalli, A., Dugnani, E., Sordi, V., Magistretti, P., Daffonchio, L., et al. (2012). CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J. Clin. Invest. 122, 3647–3651.
Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093–1095.
De Paeppe, M.E., Chu, S., Hall, S., Heger, N.E., Thanos, C., and Mao, Q. (2012). The human fetal lung xenograft: validation as model of microvascular remodeling in the postglandular lung. Pediatr. Pulmonol. 47, 1192–1203.
Graham, M.L., Bellin, M.D., Papas, K.K., Hering, B.J., and Schuurman, H.J. (2011). Species incompatibilities in the pig-to-macaque islet xenotransplant model affect transplant outcome: a comparison with allotransplantation. Xenotransplantation 18, 328–342.
Hammar, E., Parnaud, G., Bosco, D., Perriaz, N., Maedler, K., Donath, M., Rouiller, D.G., and Halban, P.A. (2004). Extracellular matrix protects pancreatic beta-cells against apoptosis: role of short- and long-term signaling pathways. Diabetes 53, 2034–2041.
Harries, L.W., McCulloch, I.J., Holley, J.E., Rawling, T.J., Welters, H.J., and Kos, K. (2013). A role for SPARC in the moderation of human insulin secretion. PLoS ONE 8, e68253.
Hoarau, E., Chandra, V., Rustin, P., Scharffmann, R., and Duvillie, B. (2014). Pro-oxidant/antioxidant balance controls pancreatic β-cell
Chem.
secretion by collagen IV and its receptor alpha1beta1. J. Biol.
Regulation of human beta-cell adhesion, motility, and insulin
Kaido, T., Yebra, M., Cirulli, V., and Montgomery, A.M. (2004).
of pancreatic cell types derived from human embryonic stem cells.
K.A., Kroon, E., et al. (2011). Cell-surface markers for the isolation
Kelly, O.G., Chan, M.Y., Martinson, L.A., Kadoya, K., Ostertag,
Iruela-Arispe, M.L. (2003). Selective binding of lectins to embry-
Jilani, S.M., Murphy, T.J., Thai, S.N., Eichmann, A., Alva, J.A., and
Jalili, R.B., Moeen Rezakhanlou, A., Hosseini-Tabatabaei, A., Ao, Z.,
Warnock, G.L., and Ghahary, A. (2011). Fibroblast populated
Li, X., Chen, H., and Epstein, P.N. (2004). Metallothionein protects
MacDougall, J.R., Croy, B.A., Chapeau, C., and Clark, D.A. (1990).
Matsuoka, T.A., Artner, I., Henderson, E., Means, A., Sander, M., and
Lindskog, C., Korsgren, O., Pontén, F., Eriksson, J.W., Johansson,
L., and Danielsson, A. (2012). Novel pancreatic beta cell-specific
Ling, Z., and Pipeleers, D.G. (1996). Prolonged exposure of human
Matsuoka, T.A., Artner, I., Henderson, E., Means, A., Sander, M., and
Matsusaka, T.A., Artner, I., Henderson, E., Means, A., Sander, M., and
Matveyenko, A.V., Georgia, S., Bhushan, A., and Butler, P.C. (2010).
Inconsistent formation and nonfunction of insulin-positive cells
Motté, E., Szepessy, E., Suenens, K., Stangé, G., Bomans, M., Jacobs-
Tulleneers-Thevissen, D., Ling, Z., Kroon, E., and Pipeleers, D.; Beta
Cell Therapy Consortium EU-FP7 (2014). Composition and function
of macromencapsulated human embryonic stem cell-derived
implants: comparison with clinical human islet cell grafts. Am. J.
Physiol. Endocrinol. Metab. 307, E838–E846.
Nagata, N., Gu, Y., Hori, H., Balamurugan, A.N., Touma, M., Kawakami, Y., Wang, W., Baba, T.T., Satake, A., Nozawa, M., et al. (2001).
Evaluation of insulin secretion of isolated rat islets cultured in
extracellular matrix. Cell Transplant. 10, 447–451.
Navarro-Alvarez, N., Rivas-Carrillo, J.D., Soto-Gutierrez, A., Yuasa, T., Okitsu, T., Noguchi, H., Matsumoto, S., Takei, J., Tanaka, N., and
Kobayashi, N. (2008). Reestablishment of microenvironment is necessary to maintain in vitro and in vivo human islet function. Cell Transplant. 17, 111–119.
Pagliuca, F.W., Millman, J.R., Gütler, M., Segel, M., Van Dervort, A., Ryu, J.H., Peterson, Q.P., Greiner, D., and Melton, D.A. (2014). Generation of functional human pancreatic β cells in vitro. Cell 159, 428–439.
Pepper, A.R., Gall, C., Mazzuca, D.M., Melling, C.W., and White, D.J. (2009). Diabetic rats and mice are resistant to porcine and human insulin: flaws experimental models for testing islet xenografts. Xenotransplantation 16, 502–510.
Pepper, A.R., Gala-Lopez, B., Ziff, O., and Shapiro, A.M. (2013). Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin. Dev. Immunol. 2013, 352315.
Rezania, A., Bruin, J.E., Riedel, M.J., Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., O’Neill, J.J., et al. (2012). Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes 61, 2016–2029.
Rezania, A., Bruin, J.E., Xu, J., Narayan, K., Fox, J.K., O’Neil, J.J., and Kieffer, T.J. (2013). Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem Cells 31, 2432–2442.
Rezania, A., Bruin, J.E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O’Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32, 1121–1133.
Robertson, R.T., Levine, S.T., Haynes, S.M., Gutierrez, P., Baratta, J.L., Tan, Z., and Longmuir, K.J. (2015). Use of labeled tomato lectin for imaging vasculature structures. Histochem. Cell Biol. 143, 225–234.
Russ, H.A., Parent, A.V., Ringer, J.J., Hennings, T.G., Nair, G.G., Sheveygert, M., Guo, T., Puri, S., Haataja, L., Cirilli, V., et al. (2015). Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro. EMBO J. 34, 1759–1772.
Salvay, D.M., Rives, C.B., Zhang, X., Chen, F., Kaufman, D.B., Lowe, W.L., Jr., and Shea, L.D. (2008). Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation 85, 1456–1464.
Shapiro, A.M. (2011). State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr. Diab. Rep. 11, 345–354.
Szot, G.L., Yadav, M., Lang, J., Kroon, E., Kerr, J., Kadoya, K., Brandon, E.P., Baetge, E.E., Bour-Jordan, H., and Bluestone, J.A. (2015).
Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell 16, 148–157.

Wang, H., Brun, T., Kataoka, K., Sharma, A.J., and Wollheim, C.B. (2007). MAFA controls genes implicated in insulin biosynthesis and secretion. Diabetologia 50, 348–358.

Yap, W.T., Salvay, D.M., Silliman, M.A., Zhang, X., Bannon, Z.G., Kaufman, D.B., Lowe, W.L., Jr., and Shea, L.D. (2013). Collagen IV-modified scaffolds improve islet survival and function and reduce time to euglycemia. Tissue Eng. Part A 19, 2361–2372.

Zhang, C., Moriguchi, T., Kajihara, M., Esaki, R., Harada, A., Shimotohata, H., Oishi, H., Hamada, M., Morito, N., Hasegawa, K., et al. (2005). MafA is a key regulator of glucose-stimulated insulin secretion. Mol. Cell. Biol. 25, 4969–4976.

Zhu, X., Orci, L., Carroll, R., Norrbom, C., Ravazzola, M., and Steiner, D.F. (2002). Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc. Natl. Acad. Sci. USA 99, 10299–10304.